Drug

ALX148 clinical trials

Also written ALX148 and evorpacept.

studies test it: 13
open now: 2
in phase 3: 1
first study started: 2020

Keep track of what changes. Save the ALX148 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Studies by the year they started

13 studies that test it; most in 2021 (5)

Studies that test ALX148, by start year
Year	Studies
2020	1
2021	5
2022	3
2023	2
2024	1
2025	1

By phase

A phase 1/2 study counts in both.

Phase 1: 6
Phase 2: 10
Phase 3: 1

What it is tested for

Each study’s main condition, where its own words name it.

Squamous Cell Carcinoma of Head and Neck: 2
Lymphoma, Follicular: 1
Ovarian Neoplasms: 1
Oropharyngeal Neoplasms: 1
Stomach Neoplasms: 1
Urinary Bladder Neoplasms: 1
Breast Neoplasms: 1
Colorectal Neoplasms: 1
Leukemia, Myeloid, Acute: 1

Who runs them

Industry 8 · Other 5

ALX Oncology Inc. (7) · M.D. Anderson Cancer Center (1) · Alexander B Olawaiye, MD (1) · University of California, San Diego (1) · Jazz Pharmaceuticals (1) · QuantumLeap Healthcare Collaborative (1) · University of Colorado, Denver (1)

Often tested with

Tested in the same studies.

Pembrolizumab (2) · Trastuzumab (2) · Zanidatamab (2) · Lenalidomide (1) · Rituximab (1) · Doxorubicin (1) · Enfortumab vedotin (1) · Trastuzumab deruxtecan (1)

Studies

Open first, then newest update. How each study uses ALX148 is read from its arms, and is right about nine times in ten.

Testing it · 13

Given in every arm · 2 — ALX148 is usual care beside what is tested

Codes

What other systems call ALX148 · ClinicalTrials.gg INT001498

MeSH (NLM) C000712178ALX148One source ClinicalTrials.gov

System	Code	Name there	Checked by
MeSH (NLM)	C000712178	ALX148	One source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.